- Home
- PRTG vs NCNA Comparison
PRTG vs NCNA Comparison
Compare PRTG & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTG
- NCNA
- Stock Information
- Founded
- PRTG 1973
- NCNA 1997
- Country
- PRTG British Virgin Islands
- NCNA United Kingdom
- Employees
- PRTG N/A
- NCNA N/A
- Industry
- PRTG Oil & Gas Production
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- PRTG Energy
- NCNA Health Care
- Exchange
- PRTG Nasdaq
- NCNA Nasdaq
- Market Cap
- PRTG 4.7M
- NCNA 4.7M
- IPO Year
- PRTG N/A
- NCNA 2017
- Fundamental
- Price
- PRTG $5.69
- NCNA $1.22
- Analyst Decision
- PRTG Hold
- NCNA Buy
- Analyst Count
- PRTG 1
- NCNA 2
- Target Price
- PRTG N/A
- NCNA $25.00
- AVG Volume (30 Days)
- PRTG 1.9M
- NCNA 90.3K
- Earning Date
- PRTG 11-26-2024
- NCNA 11-25-2024
- Dividend Yield
- PRTG N/A
- NCNA N/A
- EPS Growth
- PRTG N/A
- NCNA N/A
- EPS
- PRTG N/A
- NCNA N/A
- Revenue
- PRTG N/A
- NCNA N/A
- Revenue This Year
- PRTG N/A
- NCNA N/A
- Revenue Next Year
- PRTG N/A
- NCNA N/A
- P/E Ratio
- PRTG N/A
- NCNA N/A
- Revenue Growth
- PRTG N/A
- NCNA N/A
- 52 Week Low
- PRTG $2.10
- NCNA $1.17
- 52 Week High
- PRTG $40.80
- NCNA $19.40
- Technical
- Relative Strength Index (RSI)
- PRTG 56.00
- NCNA 35.87
- Support Level
- PRTG $5.35
- NCNA $1.17
- Resistance Level
- PRTG $12.89
- NCNA $1.31
- Average True Range (ATR)
- PRTG 1.12
- NCNA 0.06
- MACD
- PRTG 0.30
- NCNA 0.02
- Stochastic Oscillator
- PRTG 31.57
- NCNA 22.73
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.